Literature DB >> 33738544

Involvement of APRIL in Helicobacter pylori-related gastric cancer.

Qun Zhang1, Ying Ni2, Xiaofei Zhi3, Jiwei Wang4, Zheng Li4, Jie Tang5, Linjun Wang4, Weizhi Wang4, Zekuan Xu6.   

Abstract

BACKGROUND/AIMS: A proliferation-inducing ligand (APRIL, also known as TNFSF13, CD256) is a member of the tumor necrosis factor (TNF) superfamily and involved in a diverse set of diseases. In this work, we explored the potential associations and underlying mechanism in patients suffered from gastric cancer between the expression of APRIL and H. pylori infection.
METHODS: We analyzed APRIL expression levels in 200 GC tissue samples by immunohistochemistry staining. H. pylori infection was detected by modified Giemsa staining. The biological effects of APRIL on human GC cells in vitro and in vivo were tested by CCK-8 assay, colony formation, flow cytometry detection, transwell migration assay, matrigel invasion assay, and tumor xenograft assay in animals.
RESULTS: APRIL reactivity was positively correlated with H. pylori infection in vitro and vivo. It turned out that the decrease of miR-145 expression was dose-dependent and time-dependent on H. pylori infection and in consistent with APRIL expression. MiR-145 significantly attenuated the effect of H. pylori infection on APRIL gene expression in SGC7901 and BGC823 cell lines. Furthermore, APRIL overexpression promoted the proliferation, migration, invasion, and transfer of GC cells and decreased apoptosis, while APRIL knockdown suppressed these effects. We confirmed that APRIL activated the canonical NF-κB pathway through phosphorylation of AKT.
CONCLUSION: The expression of APRIL, which promoted the proliferation, migration, invasion, viability, and metastasis of GC cells, was upregulated in human H. pylori-infected GC through miR-145. Besides, APRIL-induced gastric tumorigenicity via activating NF-κB pathway. These results may provide a framework for the deeper analysis of APRIL in GC risk and prognosis.

Entities:  

Keywords:  APRIL; Gastric cancer; Helicobacter pylori; MiR-145; NF-κB pathway

Year:  2021        PMID: 33738544     DOI: 10.1007/s00432-021-03574-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  32 in total

1.  Helicobacter pylori infection and the development of gastric cancer.

Authors:  Ramy Eid; Steven F Moss
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

2.  The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer.

Authors:  P Gao; A-Y Xing; G-Y Zhou; T-G Zhang; J-P Zhang; C Gao; H Li; D-B Shi
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

Review 3.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

4.  Recent patterns in gastric cancer: a global overview.

Authors:  Paola Bertuccio; Liliane Chatenoud; Fabio Levi; Delphine Praud; Jacques Ferlay; Eva Negri; Matteo Malvezzi; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

Review 5.  Epidemiology of gastric cancer.

Authors:  Katherine D Crew; Alfred I Neugut
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

Review 6.  Is gastric cancer preventable?

Authors:  P Correa
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 7.  An APRIL to remember: novel TNF ligands as therapeutic targets.

Authors:  Stacey R Dillon; Jane A Gross; Stephen M Ansell; Anne J Novak
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

8.  Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor.

Authors:  Frédérique Deshayes; Geneviève Laprée; Alain Portier; Yolande Richard; Philippe Pencalet; Dominique Mahieu-Caputo; Philippe Horellou; Andréas Tsapis
Journal:  Oncogene       Date:  2004-04-15       Impact factor: 9.867

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Authors:  M Hahne; T Kataoka; M Schröter; K Hofmann; M Irmler; J L Bodmer; P Schneider; T Bornand; N Holler; L E French; B Sordat; D Rimoldi; J Tschopp
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  1 in total

1.  A comprehensive pancancer analysis reveals the potential value of RAR-related orphan receptor C (RORC) for cancer immunotherapy.

Authors:  Shengfu He; Jiawen Yu; Weijie Sun; Yating Sun; Mingyang Tang; Bao Meng; Yanyan Liu; Jiabin Li
Journal:  Front Genet       Date:  2022-09-15       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.